Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results

EuroInterv.2008;4:71-76.

Eberhard Grube1*, MD; Horst Sievert2, MD; Karl-Eugen Hauptmann3, MD; Ralf Mueller1, MD; Ulrich Gerckens1, MD; Lutz Buellesfeld1, MD; Junya Ako5, MD; Takao Shimohama5, MD; Marco Costa4, MD; Peter Fitzgerald5, MD

1. HELIOS Heart Center Siegburg, Siegburg, Germany; 2. Cardiovascular Center Frankfurt, Frankfurt, Germany; 3. Barmherzige Brueder-Krankenhaus Trier, Trier, Germany; 4. University of Florida Core Imaging Laboratories, Jacksonville, Florida, USA; 5. Center

Aims: The Custom NX® 36 Drug Eluting Stent (DES) System is designed to treat coronary lesions via in situ stent length customisation. The stent evaluated in th

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

biolimus a9coronary arterycustomisationdrug eluting stent

Share on Facebook Share on Twitter Share on Linkedin

Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke